WEP Clinical is pleased to announce a new partnership with Geron Corporation to make their investigational MDS treatment available through an Expanded Access Protocol (EAP). Find out more about WEP EAP services on our website: https://t.co/swGiMr0jVU

WEP Clinical is pleased to announce a new partnership with Theratechnologies Inc. to make their HIV treatment available through a Post-Approval Named Patient Program (PA-NPP). Find out more about WEP Clinical’s PA-NPP services on our website: https://t.co/swGiMr0jVU

WEP Clinical is pleased to announce a new partnership with Pharming Group N.V. to make their FDA-approved treatment available through a Post-Approval Named Patient Program (PA-NPP). Find out more about WEP Clinical’s services on our website: https://t.co/1tC6jxL5BL

Have questions about expanded access? Reach out to us today and a member of our team will be in touch with the answers you are looking for. EAP@WEPCLINICAL.COM #ExpandedAccessPrograms #CompassionateUse #ManagedAccess #TreatmentAccessSolutions #WithEveryPatient

WEP had a great first day at the World Orphan Drug Congress USA. Stop by our booth #516 during the remainder of the Congress to talk to our team about how we can help you with your expanded access, post-approval named patient, and market access needs.

It's Patient Experience Week 2023! WEP Clinical would like to acknowledge and thank the healthcare staff and patient support groups that we work with around the world. Each of you provide an invaluable service and ensure that patients receive a positive care experience!

At WEP we are With Every Patient, as we believe every patient should have access to treatment. Visit our website to find out more about the work we do to create broader treatment access solutions for patients worldwide. https://t.co/o9E7gxUfVG #WithEveryPatient

As it's National Physicians Week in the US, we would like to take the time recognize the hard work and dedication of the physicians we partner with around the world. The programs we run, that provide treatment access solutions for patients, would not be possible without them!

Download our online resource to learn more about the value of collecting Real World Data in Expanded Access Programs. https://t.co/7t8RfIEikf

Our Post-Approval Named Patient Programs allow Sponsors to provide their approved drugs in countries where they are not yet licensed or commercially available. Learn about the potential volume uptake for your product in selected markets. https://t.co/tQYdeCDomS

The WEP team had a great first day at World Orphan Drug Congress Europe. Stop by our booth #7 over the remainder of the conference to talk about how we can work with you to help create broader treatment access solutions for patients worldwide! #wodc #rarediseases #treatment

WEP is looking forward to attending The Decentralized Trials & Research Alliance (DTRA) Annual Meeting, next week in Boston. Stop by our booth and chat to Directors from our Clinical Trial Nursing Team. #dtra #decentralizedclinicaltrials #homenursing #nursingsolutions

The WEP team is looking forward to attending the upcoming #NORDSummit next week in Washington DC. Visit our booth #211 to talk about our Expanded Access and Post Approval Named Patient Programs as well as our Decentralized Clinical Trial Home Nursing Solutions.

Click the link below to check out our fact sheet providing insight into the benefits of collecting Real World Data (RWD) in Expanded Access Programs (EAPs) and outlining our company’s data collection capabilities: https://t.co/7t8RfIEikf

At WEP Clinical, our goal is to continuously provide the best service for all our customers, and it is always great for us to receive positive feedback. Check out the testimonial below from one of our EAP sponsor companies, and visit our website for more: https://t.co/nTESJq2LTm

The WEP team will be exhibiting at World Orphan Drug Congress USA next month in Boston. You can find us at booths 522 and 302. Or, reach out to us to book a one-on-one meeting: INFO@WEPCLINICAL.COM

WEP Clinical is pleased to announce a new partnership with Pharming Group to make rare disease investigational drug, leniolisib, available to patients through an Expanded Access Program (EAP). Find out more in our press release below: https://t.co/215q5XIoFe

WEP Clinical is excited to be working with Sellas Life Sciences Group to provide a Pre-Approval Access/Expanded Access Program for their lead asset, galinpepimut-S (GPS). Find out more in our press release below: https://t.co/DsI97Pqw0z

Are you interested in setting up a patient registry? WEP can work with your team to deliver a successful registry that generates meaningful data. Find out more on our website and contact us today to start the conversation. https://t.co/V76IITMFgw

We have put together a table outlining the main differences between an EAP and an OLEX study to help companies determine which option might work best for them. Check it out using the link below: https://t.co/JA6VvXUJ9U #expandedaccess #earlyaccess #managedaccess #namedpatient